1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United Kingdom >
  5. Precisio Acquires CC BIO

M&A Deal Summary

Precisio Acquires CC BIO

On March 1, 2024, Precisio acquired life science company CC BIO

Acquisition Highlights
  • This is Precisio’s 1st transaction in the Life Science sector.
  • This is Precisio’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2024-03-01
Target CC BIO
Sector Life Science
Buyer(s) Precisio
Deal Type Add-on Acquisition

Target

CC BIO

London, United Kingdom
CC BIO is an early-stage bioinformatics company. Utilizing deep expertise in synthetic biology and microbiology, CC Bio has developed Zeus™, a pioneering endolysin design platform which complements Precisio Biotix's existing LysiThru™ endolysin discovery platform. CC BIO was founded in 2018 and is based in London, England.

Search 215,074 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Precisio

United States
Category Company
Sector Life Science
DESCRIPTION

Precisio is a clinical-stage biotech company creating lower-cost novel precision precision-engineered biological antibacterials, with an initial focus on skin and lung infections. Precisio is a platform-plus-product company (Rx, consumer).

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2024 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal